Immunicum AB (publ)
Mendus AB (publ), a biopharmaceutical company, develops immunotherapies and relapse vaccines for the treatment of cancer. Its lead product is ilixadencel, which is in Phase II MERECA clinical trial for the treatment of kidney cancer; and Phase I/II clinical trial to treat liver cancer and gastrointestinal stromal tumors. The company's products also comprise DCP-001, which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia; and Phase I/II ALISON clinical trial for the treatment of ovarian cancers. It has a research collaboration with PCI Biotech Holding ASA for novel cancer vaccination treatment; and with Icahn School of Medicine at Mount Sinai. The company was formerly known as Immunicum AB (publ) and changed its name to Mendus AB (publ) in June 2022. Mendus AB (publ) was incorporated in 2002 and is headquartered in Stockholm, Sweden. Show More...
-
Website https://www.mendus.com
-
Sector Healthcare
-
Industry Biotechnology
-
Last Quote 5.28 SEK
-
Last Updated 30-05-2025
-
External Links Yahoo Finance Morningstar Ratios
-
Interest Coverage
The interest coverage ratio is a debt ratio and profitability ratio used to determine how easily a company can pay interest on its outstanding debt.
Reference: Investopedia -
2010-06 2011-06 2012-06 2013-06 2014-06 2015-06 2016-06 2017-12 2018-12 2019-12 TTM Earnings Per Share SEK -0.14 -0.16 -0.26 -0.45 -1.0 -1.66 -2.03 -3.1 -1.9 -1.5 -1.5 Dividends SEK Payout Ratio % * Shares Mil 16.0 16.0 16.0 15.0 16.0 22.0 22.0 26.0 51.0 92.0 94.0 Book Value Per Share * SEK 1.47 1.64 3.41 2.61 Free Cash Flow Per Share * SEK -1.82 -2.02 -1.39 Return on Assets % -29.77 -38.34 -33.88 -38.3 -23.75 -39.45 -39.0 -43.7 -28.1 -35.54 -40.93 Financial Leverage (Average) 1.17 1.59 1.21 1.08 1.09 1.1 1.11 1.3 1.11 1.11 1.12 Return on Equity % -34.71 -50.82 -45.54 -42.74 -25.91 -43.2 -43.1 -55.04 -32.86 -39.48 -44.21 Return on Invested Capital % -31.06 -44.46 -40.67 -41.1 -26.32 -43.2 -42.75 -54.53 -32.76 -39.38 -44.21 Interest Coverage -264.41 -133.91 -75.42 -209.15 -592.88 -292.74 Current Ratio 26.49 3.15 7.55 21.42 12.93 12.73 9.67 2.53 10.36 10.05 9.95 Quick Ratio 26.38 3.11 7.41 21.38 12.85 12.41 9.33 2.36 10.27 9.93 9.82 Debt/Equity 0.13 0.22 0.11 0.03 0.010 0.010 0.010